AKR1B1 and diabetic neuropathy: α-Lipoic acid and an aldose reductase inhibitor are available for the treatment of diabetic neuropathy in some countries and some other drugs are in clinical trials [11], but more powerful therapies are needed for the treatment of painful diabetic neuropathy not only for the relief from pain but also to improve nerve functions.